查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1413901

胶原蛋白疾病血管疾病市场：按产品、适应症和最终用途 - 全球预测 2024-2030

Collagen Vascular Diseases Market by Product (Diagnosis, Treatments), Indication (Ankylosing Spondylitis, Dermatomyositis, Polyarteritis Nodosa), End-Use - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

胶原病血管疾病市场规模预计2023年为298.3亿美元，2024年达322.1亿美元，预计2030年将达535.1亿美元，复合年增长率为8.70%。

全球胶原血管疾病市场

主要市场统计
基准年[2023] 298.3亿美元
预测年份 [2024] 322.1亿美元
预测年份 [2030] 535.1亿美元
复合年增长率（%） 8.7%
胶原蛋白疾病血管疾病市场-IMG1

胶原血管疾病是一组涉及支持器官和身体其他部位的富含蛋白质的组织的疾病。这种结缔组织对于皮肤、肌腱、骨骼、软骨和血管的强度、弹性和结构至关重要。胶原病血管疾病可能是遗传性的，也可能是由过度活跃的免疫系统引起的，导致身体攻击自身组织的自体自体免疫疾病。这些疾病通常具有通用特征，包括导致受影响器官和组织受损和功能障碍的发炎。这一类包括多种疾病，包括类风湿性关节炎、硬皮症、全身性红斑性狼疮、多发性肌炎、皮肌炎和全身性硬化症。胶原病血管疾病市场涵盖医疗解决方案的需求和供应，例如针对影响结缔组织的疾病的诊断、治疗、治疗和服务。该市场的应用包括临床诊断、治疗和持续的患者管理。最终使用者通常是医疗机构，例如医院、诊所、风湿病中心和居家照护机构。该市场也为研究和学术机构以及参与开发新治疗方法的製药和生物技术公司提供服务。影响胶原蛋白血管疾病市场需求的关键因素是：人们对胶原蛋白血管疾病的认识和理解不断提高、全球自体自体免疫疾病盛行率上升、医疗保健基础设施的改善以及医疗服务的可及性。然而，他们面临挑战，例如与先进治疗和药物相关的高成本，以及严格的政府法规和核准流程。同时，对胶原血管疾病的需求带来了一些快速增长的机会，包括基因疗法和干细胞疗法的不断进步，以及远端医疗、行动健康应用和穿戴式装置在患者管理中的采用。

区域洞察

美国因其完善的医疗基础设施、患者意识以及自体自体免疫疾病的高盛行率而成为心血管疾病的重要市场。专注于技术创新的大型製药企业的存在和政府的支持政策正在促进市场的扩张。在南美洲，随着医疗保健的改善和人们对这种疾病的认识不断提高，胶原蛋白血管疾病市场正在扩大。政府加强医疗保健服务和医学研究国际合作的措施预计将进一步提振市场。欧盟对 KEYWORD 的需求的特征是全民健保系统的可用性以及对研究和开发的重视。严格的药品核准规定确保了高标准的医疗服务。该地区的消费者期待最先进的治疗设施，并受到治疗的功效和安全性的驱动。包括胶原血管疾病在内的自体免疫疾病在中东呈上升趋势，发展中的医疗保健产业高度依赖国际指南和药物。非洲治疗胶原血管疾病的能力各不相同，许多地区这些疾病的盛行率很高，而且缺乏先进的治疗方法。随着向现代医疗保健体系的过渡，中国市场正在迅速扩张，政府和私营部门对医疗保健的投资不断增加，全球药品的获取情况也有所改善，影响了客户的需求。我是。日本市场反映了医疗保健领域技术整合的高水平，消费者基础倾向于创新和护理品质。

FPNV定位矩阵

FPNV定位矩阵对于评估胶原血管疾病市场至关重要。我们检视与业务策略和产品满意度相关的关键指标，以对供应商进行全面评估。这种深入的分析使用户能够根据自己的要求做出明智的决策。根据评估，供应商被分为四个成功程度不同的像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市场占有率分析

市场占有率分析是一种综合工具，可以对胶原病血管疾病市场供应商的现状进行深入而详细的研究。全面比较和分析供应商在整体收益、基本客群和其他关键指标方面的贡献，以便更好地了解公司的绩效及其在争夺市场占有率时面临的挑战。此外，该分析还提供了对该行业竞争特征的宝贵考察，包括在研究基准年观察到的累积、分散主导地位和合併特征等因素。这种详细程度的提高使供应商能够做出更明智的决策并制定有效的策略，从而在市场上获得竞争优势。

本报告在以下方面提供了宝贵的见解：

1-市场渗透率：提供有关主要企业所服务的市场的全面资讯。

2-市场开拓：我们深入研究利润丰厚的新兴市场，并分析它们在成熟细分市场中的渗透率。

3- 市场多元化：提供有关新产品发布、开拓地区、最新发展和投资的详细资讯。

4-竞争力评估与资讯：对主要企业的市场占有率、策略、产品、认证、监管状况、专利状况、製造能力等进行全面评估。

5- 产品开发与创新：提供对未来技术、研发活动和突破性产品开发的见解。

本报告解决了以下关键问题：

1-胶原蛋白血管疾病市场的市场规模和预测是多少？

2-在胶原病血管疾病市场预测期内需要考虑投资的产品、细分市场、应用和领域有哪些？

3-胶原血管疾病市场的技术趋势和法律规范是什么？

4-胶原病血管疾病市场主要供应商的市场占有率是多少？

5-进入胶原血管疾病市场的合适型态和策略手段是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 提高对胶原血管疾病的认识与理解
      • 全球自体自体免疫疾病发生率上升
      • 改善医疗基础设施并增加获得医疗服务的机会
    • 抑制因素
      • 与先进治疗和药物相关的高成本
    • 机会
      • 基因治疗和干细胞治疗的持续进展
      • 采用远端医疗、行动医疗应用和穿戴式装置进行病患管理
    • 任务
      • 严格的政府法规和核准流程
  • 市场区隔分析
    • 产品：切片检查套件在胶原血管疾病的使用增加
    • 适应症：扩大用作皮肌炎的适应症
    • 最终用途：在诊断中心和实验室中广泛使用，以诊断各种健康状况
  • 市场趋势分析
  • 高通膨的累积效应
  • 波特五力分析
  • 价值炼和关键路径分析
  • 法律规范

第六章胶原蛋白疾病血管疾病市场：副产品

  • 诊断
    • 切片检查
    • 验血
    • 超音波心臟检查
    • 影像检查
    • 尿液检查
  • 治疗方法
    • 药品
    • 物理治疗

第七章胶原蛋白疾病血管疾病市场（按适应症）

  • 僵直性脊椎炎
  • 皮肌炎
  • 结节性多动脉炎
  • 多发性肌炎
  • 干癣性关节炎
  • 復发性多发性软骨炎
  • 类风湿性关节炎
  • 硬皮症
  • 全身性红斑性狼疮
  • 血管炎

第八章胶原病血管疾病市场：依最终用途分类

  • 诊断中心和实验室
  • 医院和诊所

第九章 北美和南美胶原蛋白疾病血管疾病市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太地区胶原蛋白疾病血管疾病市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章欧洲、中东和非洲胶原病血管疾病市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争形势

  • FPNV定位矩阵
  • 市场占有率分析：主要企业
  • 主要企业竞争情境分析
    • 合约、合作和伙伴关係
    • 新产品发布和功能增强
    • 奖项/奖励/扩展

第13章竞争产品组合

  • 主要公司简介
    • Abbott Laboratories
    • AbbVie Inc.
    • Apollo Health and Lifestyle Limited
    • Augurex Life Sciences Corporation
    • Bayer AG
    • Beckman Coulter, Inc.
    • Bio-Rad Laboratories Inc.
    • Boehringer Ingelheim International GmbH
    • Bristol-Myers Squibb
    • Eli Lilly and Company
    • Exagen Inc.
    • F. Hoffmann-La Roche Ltd
    • Getinge AB
    • Gilead Sciences, Inc.
    • Illumina, Inc.
    • Laboratory Corporation of America Holdings
    • LeMaitre Vascular, Inc.
    • Merck KGaA
    • Novartis AG
    • PerkinElmer, Inc.
    • Pfizer Inc,
    • QIAGEN GmbH
    • Siemens AG
    • Thermo Fisher Scientific, Inc.
    • Trinity Biotech PLC
  • 主要产品系列

第十四章附录

  • 讨论指南
  • 关于许可证和定价
Product Code: MRR-144C638C8F84

[195 Pages Report] The Collagen Vascular Diseases Market size was estimated at USD 29.83 billion in 2023 and expected to reach USD 32.21 billion in 2024, at a CAGR 8.70% to reach USD 53.51 billion by 2030.

Global Collagen Vascular Diseases Market

KEY MARKET STATISTICS
Base Year [2023] USD 29.83 billion
Estimated Year [2024] USD 32.21 billion
Forecast Year [2030] USD 53.51 billion
CAGR (%) 8.7%
Collagen Vascular Diseases Market - IMG1

Collagen vascular diseases comprise a group of disorders that involve the protein-rich tissue that supports organs and other parts of the body. This connective tissue is essential for the strength, elasticity, and structure of skin, tendons, bones, cartilage, and blood vessels. Collagen vascular diseases can be hereditary or caused by an overactive immune system, resulting in autoimmune conditions where the body attacks its own tissues. These diseases often share common features, including inflammation, which can damage and dysfunction of affected organs and tissues. The category encompasses a variety of conditions, including rheumatoid arthritis, scleroderma, systemic lupus erythematosus, polymyositis, dermatomyositis, and systemic sclerosis, among others. The market for collagen vascular diseases encompasses the demand and supply of medical solutions, including diagnostics, treatments, therapeutics, and services targeted towards diseases that affect connective tissue. Applications for this market include clinical diagnostics, therapeutic treatments, and ongoing patient management. End-users are typically healthcare facilities like hospitals, clinics, specialized rheumatology centers, and home care settings. This market also serves research and academic institutions and pharmaceutical and biotechnology companies involved in the development of new treatments. The key factors influencing the need for the collagen vascular diseases market include growing awareness and understanding of collagen vascular diseases, rising incidence of autoimmune diseases globally, improved healthcare infrastructure, and increased accessibility to medical services. However, the market faces challenges, such as high costs associated with advanced treatments and medications and stringent government regulations and approval processes. On the other hand, the need for collagen vascular diseases presents several burgeoning opportunities, such as ongoing advancements in gene and stem cell therapies and the adoption of telemedicine, mobile health applications, and wearables for patient management.

Regional Insights

The United States represents a significant market for collagen vascular diseases (CVDs), driven by a well-established healthcare infrastructure, patient awareness, and a high incidence of autoimmune diseases. The presence of leading pharmaceutical companies focusing on innovation, coupled with supportive government policies, contributes to market expansion. In South America, the collagen vascular diseases market is expanding as healthcare access improves and the population becomes more aware of these diseases. Government initiatives to strengthen healthcare provision and international collaborations for medical research are expected to propel the market further. The EU's need for collagen vascular diseases is characterized by the availability of universal healthcare systems and a strong focus on research and development. Stringent regulations regarding drug approvals ensure a high standard of care. Consumers in this region expect state-of-the-art treatment facilities and are driven by the effectiveness and safety profiles of treatments. The Middle East is experiencing a rise in autoimmune disorders, including collagen vascular diseases, and due to a developing healthcare sector, there is a reliance on international guidelines and medications. Africa's capacity to manage collagen vascular diseases is varied, with a greater prevalence of these conditions and a scarcity of advanced treatments in many regions. China's market is rapidly expanding with a shift towards modern healthcare systems, and increased investment in healthcare by the government and private sector, paired with greater access to global pharmaceuticals, is influencing customer needs. Japan's market reflects a high degree of technological integration in healthcare, with a consumer base inclined towards innovation and treatment quality.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Collagen Vascular Diseases Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Collagen Vascular Diseases Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Collagen Vascular Diseases Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Apollo Health and Lifestyle Limited, Augurex Life Sciences Corporation, Bayer AG, Beckman Coulter, Inc., Bio-Rad Laboratories Inc., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb, Eli Lilly and Company, Exagen Inc., F. Hoffmann-La Roche Ltd, Getinge AB, Gilead Sciences, Inc., Illumina, Inc., Laboratory Corporation of America Holdings, LeMaitre Vascular, Inc., Merck KGaA, Novartis AG, PerkinElmer, Inc., Pfizer Inc,, QIAGEN GmbH, Siemens AG, Thermo Fisher Scientific, Inc., and Trinity Biotech PLC.

Market Segmentation & Coverage

This research report categorizes the Collagen Vascular Diseases Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Product
    • Diagnosis
      • Biopsy
      • Blood Test
      • Echocardiogram
      • Imaging Tests
      • Urinalysis
    • Treatments
      • Medications
      • Physical Therapy
  • Indication
    • Ankylosing Spondylitis
    • Dermatomyositis
    • Polyarteritis Nodosa
    • Polymyositis
    • Psoriatic Arthritis
    • Relapsing Polychondritis
    • Rheumatoid Arthritis
    • Scleroderma
    • Systemic Lupus Erythematosus
    • Vasculitis
  • End-Use
    • Diagnostic Centers & Laboratories
    • Hospitals & Clinics
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Collagen Vascular Diseases Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Collagen Vascular Diseases Market?

3. What are the technology trends and regulatory frameworks in the Collagen Vascular Diseases Market?

4. What is the market share of the leading vendors in the Collagen Vascular Diseases Market?

5. Which modes and strategic moves are suitable for entering the Collagen Vascular Diseases Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Collagen Vascular Diseases Market, by Region

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing awareness and understanding of collagen vascular diseases
      • 5.1.1.2. Rising incidence of autoimmune diseases globally
      • 5.1.1.3. Improved healthcare infrastructure and increased accessibility to medical services
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated with advanced treatments and medications
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing advancements in gene and stem cell therapies
      • 5.1.3.2. Adoption of telemedicine, mobile health applications, and wearables for patient management
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent government regulations and approval processes
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Product: Increasing usage of biopsy kits in collagen vascular diseases
    • 5.2.2. Indication: Increasing utilization for indicating dermatomyositis
    • 5.2.3. End-Use: Expanding usage among diagnostic centers & laboratories to diagnose various health conditions
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework

6. Collagen Vascular Diseases Market, by Product

  • 6.1. Introduction
  • 6.2. Diagnosis
    • 6.3.1. Biopsy
    • 6.3.2. Blood Test
    • 6.3.3. Echocardiogram
    • 6.3.4. Imaging Tests
    • 6.3.5. Urinalysis
  • 6.3. Treatments
    • 6.4.1. Medications
    • 6.4.2. Physical Therapy

7. Collagen Vascular Diseases Market, by Indication

  • 7.1. Introduction
  • 7.2. Ankylosing Spondylitis
  • 7.3. Dermatomyositis
  • 7.4. Polyarteritis Nodosa
  • 7.5. Polymyositis
  • 7.6. Psoriatic Arthritis
  • 7.7. Relapsing Polychondritis
  • 7.8. Rheumatoid Arthritis
  • 7.9. Scleroderma
  • 7.10. Systemic Lupus Erythematosus
  • 7.11. Vasculitis

8. Collagen Vascular Diseases Market, by End-Use

  • 8.1. Introduction
  • 8.2. Diagnostic Centers & Laboratories
  • 8.3. Hospitals & Clinics

9. Americas Collagen Vascular Diseases Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Collagen Vascular Diseases Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Collagen Vascular Diseases Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. FPNV Positioning Matrix
  • 12.2. Market Share Analysis, By Key Player
  • 12.3. Competitive Scenario Analysis, By Key Player
    • 12.3.1. Agreement, Collaboration, & Partnership
      • 12.3.1.1. Quest Diagnostics and Scipher Medicine Collaborate to Scale Precision Medicine Access for Patients with Rheumatoid Arthritis
    • 12.3.2. New Product Launch & Enhancement
      • 12.3.2.1. American College of Rheumatology Launches New Toolkit Aimed at Measuring Rheumatoid Arthritis Outcomes
    • 12.3.3. Award, Recognition, & Expansion
      • 12.3.3.1. FDA Approves First Tocilizumab Biosimilar For Treatment Of Rheumatoid Arthritis, JIA

13. Competitive Portfolio

  • 13.1. Key Company Profiles
    • 13.1.1. Abbott Laboratories
    • 13.1.2. AbbVie Inc.
    • 13.1.3. Apollo Health and Lifestyle Limited
    • 13.1.4. Augurex Life Sciences Corporation
    • 13.1.5. Bayer AG
    • 13.1.6. Beckman Coulter, Inc.
    • 13.1.7. Bio-Rad Laboratories Inc.
    • 13.1.8. Boehringer Ingelheim International GmbH
    • 13.1.9. Bristol-Myers Squibb
    • 13.1.10. Eli Lilly and Company
    • 13.1.11. Exagen Inc.
    • 13.1.12. F. Hoffmann-La Roche Ltd
    • 13.1.13. Getinge AB
    • 13.1.14. Gilead Sciences, Inc.
    • 13.1.15. Illumina, Inc.
    • 13.1.16. Laboratory Corporation of America Holdings
    • 13.1.17. LeMaitre Vascular, Inc.
    • 13.1.18. Merck KGaA
    • 13.1.19. Novartis AG
    • 13.1.20. PerkinElmer, Inc.
    • 13.1.21. Pfizer Inc,
    • 13.1.22. QIAGEN GmbH
    • 13.1.23. Siemens AG
    • 13.1.24. Thermo Fisher Scientific, Inc.
    • 13.1.25. Trinity Biotech PLC
  • 13.2. Key Product Portfolio

14. Appendix

  • 14.1. Discussion Guide
  • 14.2. License & Pricing

LIST OF FIGURES

  • FIGURE 1. COLLAGEN VASCULAR DISEASES MARKET RESEARCH PROCESS
  • FIGURE 2. COLLAGEN VASCULAR DISEASES MARKET SIZE, 2023 VS 2030
  • FIGURE 3. COLLAGEN VASCULAR DISEASES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. COLLAGEN VASCULAR DISEASES MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. COLLAGEN VASCULAR DISEASES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. COLLAGEN VASCULAR DISEASES MARKET DYNAMICS
  • FIGURE 7. COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 8. COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 10. COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
  • FIGURE 12. COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS COLLAGEN VASCULAR DISEASES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 14. AMERICAS COLLAGEN VASCULAR DISEASES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 16. UNITED STATES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. ASIA-PACIFIC COLLAGEN VASCULAR DISEASES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. ASIA-PACIFIC COLLAGEN VASCULAR DISEASES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. COLLAGEN VASCULAR DISEASES MARKET, FPNV POSITIONING MATRIX, 2023
  • FIGURE 22. COLLAGEN VASCULAR DISEASES MARKET SHARE, BY KEY PLAYER, 2023

LIST OF TABLES

  • TABLE 1. COLLAGEN VASCULAR DISEASES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. COLLAGEN VASCULAR DISEASES MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 6. COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 8. COLLAGEN VASCULAR DISEASES MARKET SIZE, BY BIOPSY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. COLLAGEN VASCULAR DISEASES MARKET SIZE, BY BLOOD TEST, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. COLLAGEN VASCULAR DISEASES MARKET SIZE, BY ECHOCARDIOGRAM, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. COLLAGEN VASCULAR DISEASES MARKET SIZE, BY IMAGING TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. COLLAGEN VASCULAR DISEASES MARKET SIZE, BY URINALYSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 15. COLLAGEN VASCULAR DISEASES MARKET SIZE, BY MEDICATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PHYSICAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 18. COLLAGEN VASCULAR DISEASES MARKET SIZE, BY ANKYLOSING SPONDYLITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DERMATOMYOSITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. COLLAGEN VASCULAR DISEASES MARKET SIZE, BY POLYARTERITIS NODOSA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. COLLAGEN VASCULAR DISEASES MARKET SIZE, BY POLYMYOSITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PSORIATIC ARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. COLLAGEN VASCULAR DISEASES MARKET SIZE, BY RELAPSING POLYCHONDRITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. COLLAGEN VASCULAR DISEASES MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. COLLAGEN VASCULAR DISEASES MARKET SIZE, BY SCLERODERMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. COLLAGEN VASCULAR DISEASES MARKET SIZE, BY SYSTEMIC LUPUS ERYTHEMATOSUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. COLLAGEN VASCULAR DISEASES MARKET SIZE, BY VASCULITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 29. COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSTIC CENTERS & LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. COLLAGEN VASCULAR DISEASES MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS COLLAGEN VASCULAR DISEASES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 39. ARGENTINA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 40. ARGENTINA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 41. ARGENTINA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 42. BRAZIL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 43. BRAZIL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 44. BRAZIL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 45. BRAZIL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 46. BRAZIL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 47. CANADA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 48. CANADA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 49. CANADA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 50. CANADA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 51. CANADA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 52. MEXICO COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 53. MEXICO COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 54. MEXICO COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 55. MEXICO COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 56. MEXICO COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 57. UNITED STATES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 58. UNITED STATES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 59. UNITED STATES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 60. UNITED STATES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 61. UNITED STATES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 62. UNITED STATES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 63. ASIA-PACIFIC COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 64. ASIA-PACIFIC COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 65. ASIA-PACIFIC COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 66. ASIA-PACIFIC COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 67. ASIA-PACIFIC COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 68. ASIA-PACIFIC COLLAGEN VASCULAR DISEASES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 69. AUSTRALIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 70. AUSTRALIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 71. AUSTRALIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 72. AUSTRALIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 73. AUSTRALIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 74. CHINA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 75. CHINA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 76. CHINA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 77. CHINA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 78. CHINA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 79. INDIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 80. INDIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 81. INDIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 82. INDIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 83. INDIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 84. INDONESIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 85. INDONESIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 86. INDONESIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 87. INDONESIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 88. INDONESIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 89. JAPAN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 90. JAPAN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 91. JAPAN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 92. JAPAN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 93. JAPAN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 94. MALAYSIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 95. MALAYSIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 96. MALAYSIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 97. MALAYSIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 98. MALAYSIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 99. PHILIPPINES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 100. PHILIPPINES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 101. PHILIPPINES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 102. PHILIPPINES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 103. PHILIPPINES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 104. SINGAPORE COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 105. SINGAPORE COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 106. SINGAPORE COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 107. SINGAPORE COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 108. SINGAPORE COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 109. SOUTH KOREA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 110. SOUTH KOREA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 111. SOUTH KOREA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 112. SOUTH KOREA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 113. SOUTH KOREA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 114. TAIWAN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 115. TAIWAN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 116. TAIWAN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 117. TAIWAN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 118. TAIWAN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 119. THAILAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 120. THAILAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 121. THAILAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 122. THAILAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 123. THAILAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 124. VIETNAM COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 125. VIETNAM COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 126. VIETNAM COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 127. VIETNAM COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 128. VIETNAM COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 135. DENMARK COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 136. DENMARK COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 137. DENMARK COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 138. DENMARK COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 139. DENMARK COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 140. EGYPT COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 141. EGYPT COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 142. EGYPT COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 143. EGYPT COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 144. EGYPT COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 145. FINLAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 146. FINLAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 147. FINLAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 148. FINLAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 149. FINLAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 150. FRANCE COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 151. FRANCE COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 152. FRANCE COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 153. FRANCE COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 154. FRANCE COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 155. GERMANY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 156. GERMANY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 157. GERMANY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 158. GERMANY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 159. GERMANY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 160. ISRAEL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 161. ISRAEL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 162. ISRAEL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 163. ISRAEL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 164. ISRAEL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 165. ITALY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 166. ITALY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 167. ITALY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 168. ITALY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 169. ITALY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 170. NETHERLANDS COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 171. NETHERLANDS COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 172. NETHERLANDS COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 173. NETHERLANDS COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 174. NETHERLANDS COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 175. NIGERIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 176. NIGERIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 177. NIGERIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 178. NIGERIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 179. NIGERIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 180. NORWAY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 181. NORWAY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 182. NORWAY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 183. NORWAY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 184. NORWAY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 185. POLAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 186. POLAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 187. POLAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 188. POLAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 189. POLAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 190. QATAR COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 191. QATAR COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 192. QATAR COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 193. QATAR COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 194. QATAR COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 195. RUSSIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 196. RUSSIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 197. RUSSIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 198. RUSSIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 199. RUSSIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 200. SAUDI ARABIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 201. SAUDI ARABIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 202. SAUDI ARABIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 203. SAUDI ARABIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 204. SAUDI ARABIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 205. SOUTH AFRICA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 206. SOUTH AFRICA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 207. SOUTH AFRICA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 208. SOUTH AFRICA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 209. SOUTH AFRICA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 210. SPAIN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 211. SPAIN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 212. SPAIN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 213. SPAIN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 214. SPAIN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 215. SWEDEN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 216. SWEDEN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 217. SWEDEN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 218. SWEDEN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 219. SWEDEN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 220. SWITZERLAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 221. SWITZERLAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 222. SWITZERLAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 223. SWITZERLAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 224. SWITZERLAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 225. TURKEY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 226. TURKEY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 227. TURKEY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 228. TURKEY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 229. TURKEY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 230. UNITED ARAB EMIRATES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 231. UNITED ARAB EMIRATES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 232. UNITED ARAB EMIRATES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 233. UNITED ARAB EMIRATES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 234. UNITED ARAB EMIRATES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 235. UNITED KINGDOM COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 236. UNITED KINGDOM COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 237. UNITED KINGDOM COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2030 (USD MILLION)
  • TABLE 238. UNITED KINGDOM COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 239. UNITED KINGDOM COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 240. COLLAGEN VASCULAR DISEASES MARKET, FPNV POSITIONING MATRIX, 2023
  • TABLE 241. COLLAGEN VASCULAR DISEASES MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 242. COLLAGEN VASCULAR DISEASES MARKET LICENSE & PRICING